• Mirna Therapeutics Inc., of Austin, Texas, reported data demonstrating that microRNA-34 (miR-34) mimics inhibited tumor growth in an animal model of B-cell lymphoma. The data, published in Leukemia, complemented those generated by Mirna and academic collaborators in animal models of lung and prostate cancer.